http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008141913-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2006-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2008141913-A |
| titleOfInvention | VACCINE FOR THERAPEUTIC OR PREVENTIVE TREATMENT OF SEVERE PSEUDOPARALITIC MYASTENIA |
| abstract | 1. A complementary peptide having at least a sequence complementary to the main immunogenic region of the acetylcholine receptor involved in severe pseudoparalytic myasthenia gravis (myasthenia gravis), characterized in that this complementary peptide has at least the sequence of SEQ ID NO: 1 s tryptophan at position 8, bearing at least one optionally substituted hydrocarbon group. ! 2. The complementary peptide according to claim 1, wherein said at least one optionally substituted hydrocarbon group is preferably an optionally substituted aryl group or an optionally substituted alkyl group, in particular an optionally substituted benzyl group, more preferably a benzyl group substituted by at least , one alkoxy group, most preferably a 2,4,6-trimethoxybenzyl group. ! 3. The complementary peptide according to claim 1, where the sequence of SEQ ID NO: 1 is complementary to residues 61-76 of the α chain of the indicated main immunogenic region of the acetylcholine receptor. ! 4. A therapeutic composition comprising the complementary peptide according to claim 1 and at least one carrier. ! 5. A therapeutic composition comprising the complementary peptide according to claim 1 and a complementary peptide having at least the sequence of SEQ ID NO: 2, complementary to the T-cell acetylcholine receptor recognition site, as well as at least one carrier. ! 6. The therapeutic composition according to claim 5, wherein the sequence of SEQ ID NO: 2 is complementary to residues 100-116 of the α chain of said T cell acetylcholine receptor recognition site. ! 7. The therapeutic composition according to claim 5, containing the first and Tue |
| priorityDate | 2006-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.